{
    "clinical_study": {
        "@rank": "158286", 
        "brief_summary": {
            "textblock": "To determine the time course of development of resistance to atevirdine mesylate ( U-87201E\n      ) in patients with HIV isolates showing in vitro resistance to zidovudine ( AZT ). To\n      determine the genotype changes in HIV reverse transcriptase associated with in vitro AZT\n      resistance to U-87201E. To determine the genotype and phenotype effects of treatment with a\n      nondideoxynucleoside agent on the alterations of the HIV-1 population associated with in\n      vitro AZT resistance. To determine whether serial passage of patient pre-drug HIV isolates\n      in the presence of U-87201E will generate the resistant mutants that may subsequently emerge\n      in the patients."
        }, 
        "brief_title": "Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Enrollment on protocol RV-43 (AZT resistance study).\n\n          -  Development of a primary RV-43 study endpoint-opportunistic infection.\n\n          -  HIV isolate with an AZT IC50 > 50 times that of the  sensitive type strain.\n\n          -  Able to swallow tablets without difficulty.\n\n          -  Normal QTc interval on EKG.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Clinically significant hypersensitivity to piperazine type drugs (Antepar,\n             Stelazine).\n\n          -  Severe uncontrollable diarrhea or vomiting or known malabsorption.\n\n          -  Symptomatic hyperlipidemia.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other experimental drugs.\n\n          -  AZT, ddI, ddC, foscarnet, immunomodulators or other agents with primary\n             antiretroviral activity (exemptions by principal investigator permitted).\n\n        Patients with the following prior conditions are excluded:\n\n        History of clinically significant cardiovascular disease or nervous system or muscle\n        disease, including seizures, peripheral neuropathy, dementia, or motor dysfunction.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Experimental drugs within 4 weeks prior to study entry."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002094", 
            "org_study_id": "117A", 
            "secondary_id": "M/3330/0007"
        }, 
        "intervention": {
            "intervention_name": "Atevirdine mesylate", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Virus Replication", 
            "Acquired Immunodeficiency Syndrome", 
            "Antiviral Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "208995000"
                }, 
                "name": "Natl Naval Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002094"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pharmacia and Upjohn", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1993"
    }, 
    "geocoordinates": {
        "Natl Naval Med Ctr": "38.985 -77.095"
    }
}